Please wait
Healthcare · Drug Manufacturers - General · Price, fundamentals, signals, and forward-looking context in one research view.
Healthcare
$159B
6.2%
36.79
Current price
$28.46
+1.8% 31 AugLast session 31 Aug · Checked 15 min ago
Open
$28.00
Previous close
$27.96
Day range
$27.64 – $28.70
Volume
N/A
36.8x P/E
Awaiting filing
6.2% yield
65/100 measured
Moderate liquidity
PFE has a positive bias over 30 days and positive bias over one year.
7-day forecast is free
You can use the full 7-day forecast on the free plan. Upgrade to Pro to unlock the 30-day and 1-year views.
Expected move
+2.41%
Expected price
$29.15
Lower path
$27.99
Upper path
$30.31
Confidence
Whisone is bullish because fundamentals are solid at 71/100 while there is no strong bear warning from the current data. Whisone has moderate conviction here. The final read is being balanced by the weighted scores for fundamentals, technicals, insider flow, sentiment, event flow, and liquidity.
Whisone v2 splits the read into weighted parts so the score is not just one hidden number.
Fundamentals
Growth, margins, cash flow, and valuation.
Latest net profit
-$248M
TTM (2026-06-30)
ROE
5.0%
Return on equity
ROA
5.8%
Return on assets
Debt / equity
0.74
Lower is usually safer.
P/B ratio
1.87
Useful for book value support.
Dividend yield
6.2%
Current income signal.
85/100
Direction
Positive bias
Main supports
Business quality and balance-sheet strength are supporting the outlook.
Recent price behavior and momentum still support follow-through.
Trading liquidity looks supportive for the forecast to transmit into price action.
What can go wrong
Execution risk and market swings can still delay the forecast playing out.
Fair value
$28.28
Analyst view
Buy
Analyst target
$28.61
Forecast refresh
Updated 15 min ago
Quality score
70
Growth score
50
These are the external analyst numbers and business outlook figures already synced into the company record.
No external analyst outlook is available for this company yet.
$0.43
2025-01-24
Payment: TBA | Qualification: 2025-01-24 | Yield at declaration: N/A
$0.42
2024-11-08
Payment: TBA | Qualification: 2024-11-08 | Yield at declaration: N/A
A plain-English reading of momentum, trend, volatility, range position, and trading participation.
RSI
N/A
Momentum data is not available yet.
Recent trend
Rising
+13.8% across the latest saved price window.
Volatility
Low
Beta is 0.28. Price has historically moved more calmly than the wider market.
52-week position
94% of range
Price is trading close to its 52-week high.
Volume confirmation
N/A
Comparable volume data is not available.
high_energy_costs
PFE may also move because the HEALTHCARE sector may move with high_energy_costs. Confidence 63%.
PMG-MAN stated the pharmaceutical sector spends a large share of revenue on energy, reducing competitiveness industry-wide.
q1_2026_gdp_growth
PFE may also move because the HEALTHCARE sector may move with q1_2026_gdp_growth. Confidence 63%.
NBS data cited in the article shows the healthcare sector grew by 1.99% in Q1 2026 (vs 1.76% in Q1 2025), indicating sector-level growth dynamics affecting listed healthcare firms.
policy_stability_and_support
PFE may also move because the HEALTHCARE sector may benefit from policy_stability_and_support. Confidence 60%.
The sector would benefit from extended Presidential Executive Order, dedicated energy tariffs, and policies encouraging local API production to attract investment and boost local manufacturing.
local manufacturing / import substitution
PFE may also move because the HEALTHCARE sector may benefit from local manufacturing / import substitution. Confidence 56%.
The article notes Nigeria's pharmaceutical firms are investing in local manufacturing and import substitution to reduce dependence on foreign supply, a trend that supports domestic pharma firms' growth and access.
local_manufacturing_and_access
PFE may also move because the HEALTHCARE sector may benefit from local_manufacturing_and_access. Confidence 56%.
MeCure's emphasis on affordable, locally manufactured medicines and wider market penetration illustrates sector-level support for improved local manufacturing and access to quality medicines.
manufacturing infrastructure
PFE may also move because the HEALTHCARE sector may benefit from manufacturing infrastructure. Confidence 56%.
Completion of a pharmaceutical manufacturing facility by Neimeth increases manufacturing capacity in the healthcare sector.
local_manufacturing_and_product_innovation
PFE may also move because the HEALTHCARE sector may move with local_manufacturing_and_product_innovation. Confidence 53%.
MeCure's focus on deepening local manufacturing, product innovation, and expanded market penetration reflects sector-wide themes of local production and access to affordable medicines.
profit-taking
PFE may also move because the HEALTHCARE sector may move with profit-taking. Confidence 53%.
Profit-taking is identified in the article as a trigger for the sell-off impacting SWOOT stocks.
PFE
Pfizer Inc.
Price: $28.46
P/E: 36.789474
Yield: 6.2%
ABBV
AbbVie Inc.
Price: $256.42
P/E: 72.23099
Yield: 2.7%
ABT
Abbott Laboratories
Price: $110.36
P/E: 35.71521
Yield: 2.2%
ALGN
Align Technology, Inc.
Price: $159.79
P/E: 27.69324
Yield: 0.0%
Industry
Drug Manufacturers - General
Employees
75000
Exchange
NYQ
Ticker
PFE
